von Heyden H W, Beyer J H, Matthaei A, Nagel G A, Schröder M
Onkologie. 1981 Dec;4(6):296-9. doi: 10.1159/000214942.
The preliminary results of a controlled study for treatment of 33 patients with squamous cell carcinoma of the head and neck region with regimen A: cis-DDP (3 mg/M2 dl) plus Bleomycin (15 mg/m2 i.v. continuously d2-6) against regimen B: Methotrexate (30 mg/m2 i.v. dl + 6) and vindesine (3 mg/m2 i.v. dl + 7) were as follows: complete remission (cr): 1 X A, 0 X B; partial remission (pr): 6 X A, 4 X B; minor response (mr): 3 X A, 7 X B; no change (nc): 2 X A, 0 X B; progression (pg): 5 X A, 5 X B. Due to progressive disease 8 patients were further treated with the alternative regimen with following results: cr: 1 X A; mr: 1 X A, 2 X B; nc: 1 X B; pg: 3 X A. Considering prognostic factors it could be demonstrated that primary chemotherapy (pc) was more effective that applied after operation and/or radiotherapy (secondary chemotherapy = sc): cr + pr: (= 53%), 4 X sc (= 22%); nc + pg: 1 X pc (= 7%), 7 X sc (= 39%).
一项对照研究的初步结果显示,用方案A(顺铂3mg/M²,第1日静脉滴注;博来霉素15mg/m²,第2至6日持续静脉滴注)治疗33例头颈部鳞状细胞癌患者,与方案B(甲氨蝶呤30mg/m²,第1日和第6日静脉滴注;长春地辛3mg/m²,第1日和第7日静脉滴注)相比,结果如下:完全缓解(CR):方案A 1例,方案B 0例;部分缓解(PR):方案A 6例,方案B 4例;轻度缓解(MR):方案A 3例,方案B 7例;无变化(NC):方案A 2例,方案B 0例;病情进展(PG):方案A 5例,方案B 5例。由于病情进展,8例患者改用替代方案进一步治疗,结果如下:CR:方案A 1例;MR:方案A 1例,方案B 2例;NC:方案B 1例;PG:方案A 3例。考虑预后因素,可以证明,与术后和/或放疗后应用的化疗(辅助化疗=SC)相比,新辅助化疗(PC)更有效:CR+PR:PC组4例(53%),SC组4例(22%);NC+PG:PC组1例(7%),SC组7例(39%)。